Logo

Merck Entered into Clinical Trial Collaboration with Carisma to Evaluate Keytruda (pembrolizumab) + CAR-M for HER2 Positive Cancers

Share this

Merck Entered into Clinical Trial Collaboration with Carisma to Evaluate Keytruda (pembrolizumab) + CAR-M for HER2 Positive Cancers

Shots:

  • The companies collaborated to evaluate Carisma’s CAR-M + Merck’s Keytruda for HER2 overexpressing cancers patients. The study is expected to launch in 2022
  • Carisma's CAR-M platform can reprogram the solid tumor microenvironment for immune activation, T cell recruitment & anti-tumor adaptive immunity, based on pre-clinical results
  • In preliminary results, CT-0508 was well tolerated after infusion & no dose-limiting toxicities were observed, and showed high CAR expression while immunotherapy was successfully manufactured using macrophages from heavily pretreated, advanced solid tumor patients. Additionally, CT-0508 has received FTD from the US FDA for solid tumors

Ref: PR Newswire | Image: Merck

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions